NCT01564251View on ClinicalTrials.gov

A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 23, 2012

Primary Completion Date

January 11, 2018

Study Completion Date

January 11, 2018

Conditions
Lymphoma, Solid Tumor
Interventions
DRUG

GDC-0575

Participants will receive GDC-0575 orally at a starting dose of 15 mg.

DRUG

Gemcitabine

Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.

Trial Locations (7)

33076

Institut Bergonie; Oncologie, Bordeaux

37203

The Sarah Cannon Research Inst, Nashville

48201

Karmanos Cancer Institute, Detroit

73104

University of Oklahoma Health Sciences Center, Oklahoma City

94805

Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif

06520

Yale Cancer Center, New Haven

02215

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY